137 related articles for article (PubMed ID: 20093186)
21. Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever.
Lee DG; Chae H; Yim DS; Park SH; Choi SM; Kim S; Choi JH; Yoo JH; Shin WS
J Clin Pharm Ther; 2009 Jun; 34(3):337-44. PubMed ID: 19646080
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice.
Tansho S; Abe S; Ishibashi H; Torii S; Otani H; Ono Y; Yamaguchi H
J Infect Chemother; 2006 Dec; 12(6):355-62. PubMed ID: 17235640
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation.
Mouton JW; van Peer A; de Beule K; Van Vliet A; Donnelly JP; Soons PA
Antimicrob Agents Chemother; 2006 Dec; 50(12):4096-102. PubMed ID: 16982783
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of inclusion complexes of prazosin hydrochloride with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
Liu L; Zhu S
J Pharm Biomed Anal; 2006 Jan; 40(1):122-7. PubMed ID: 16095859
[TBL] [Abstract][Full Text] [Related]
25. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution.
Tolman JA; Nelson NA; Son YJ; Bosselmann S; Wiederhold NP; Peters JI; McConville JT; Williams RO
Eur J Pharm Biopharm; 2009 May; 72(1):199-205. PubMed ID: 19348016
[TBL] [Abstract][Full Text] [Related]
26. Formulation of rifampicin-cyclodextrin complexes for lung nebulization.
Tewes F; Brillault J; Couet W; Olivier JC
J Control Release; 2008 Jul; 129(2):93-9. PubMed ID: 18514353
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.
Quinney SK; Galinsky RE; Jiyamapa-Serna VA; Chen Y; Hamman MA; Hall SD; Kimura RE
Drug Metab Dispos; 2008 Jun; 36(6):1097-101. PubMed ID: 18339815
[TBL] [Abstract][Full Text] [Related]
28. Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement.
Tao T; Zhao Y; Wu J; Zhou B
Int J Pharm; 2009 Feb; 367(1-2):109-14. PubMed ID: 18930795
[TBL] [Abstract][Full Text] [Related]
29. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide.
Elgindy N; Elkhodairy K; Molokhia A; Elzoghby A
Eur J Pharm Biopharm; 2010 Feb; 74(2):397-405. PubMed ID: 19944160
[TBL] [Abstract][Full Text] [Related]
30. Electrospinning of polymer-free nanofibers from cyclodextrin inclusion complexes.
Celebioglu A; Uyar T
Langmuir; 2011 May; 27(10):6218-26. PubMed ID: 21513339
[TBL] [Abstract][Full Text] [Related]
31. Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.
Maincent JP; Najvar LK; Kirkpatrick WR; Huang S; Patterson TF; Wiederhold NP; Peters JI; Williams RO
Drug Dev Ind Pharm; 2017 Feb; 43(2):264-274. PubMed ID: 27645428
[TBL] [Abstract][Full Text] [Related]
32. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing.
Overhoff KA; Moreno A; Miller DA; Johnston KP; Williams RO
Int J Pharm; 2007 May; 336(1):122-32. PubMed ID: 17184938
[TBL] [Abstract][Full Text] [Related]
33. A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics.
Yi Y; Yoon HJ; Kim BO; Shim M; Kim SO; Hwang SJ; Seo MH
J Control Release; 2007 Jan; 117(1):59-67. PubMed ID: 17097755
[TBL] [Abstract][Full Text] [Related]
34. Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole.
Mino Y; Naito T; Watanabe T; Yamada T; Yagi T; Yamada H; Kawakami J
Clin Chim Acta; 2013 Jan; 415():128-32. PubMed ID: 23089073
[TBL] [Abstract][Full Text] [Related]
35. Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat.
Rajendrakumar K; Madhusudan S; Pralhad T
Eur J Pharm Biopharm; 2005 May; 60(1):39-46. PubMed ID: 15848054
[TBL] [Abstract][Full Text] [Related]
36. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.
Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
Pharmacotherapy; 1998; 18(2):295-301. PubMed ID: 9545149
[TBL] [Abstract][Full Text] [Related]
37. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
38. Dry powder inhaler formulations of poorly water-soluble itraconazole: A balance between in-vitro dissolution and in-vivo distribution is necessary.
Huang Z; Lin L; McGoverin C; Liu H; Wang L; Zhou QT; Lu M; Wu C
Int J Pharm; 2018 Nov; 551(1-2):103-110. PubMed ID: 30217767
[TBL] [Abstract][Full Text] [Related]
39. NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols.
Pornputtapitak W; El-Gendy N; Berkland C
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):341-52. PubMed ID: 25679514
[TBL] [Abstract][Full Text] [Related]
40. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
Zuo Z; Tam YK; Diakur J; Wiebe LI
J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
